Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CRWE & MIPI - Stock Alerts! from Stock-Pr.com - Crown Equity Holdings & Molecular Insight Pharmaceuticals

 

Stock-PR Reporting

stockpr_logo-site

 

FREE Daily Stock Alerts From Stock-PR.com

chartstockalert

________________________________________

 

 

___

  Molecular Insight Pharmaceuticals, Inc. (NASDAQ:MIPI)

MIPI, this week presented positive data from Phase 1 clinical studies comparing Trofex, its lead molecular imaging candidate for the diagnosis and monitoring of metastatic prostate cancer, and ProstaScint, an imaging radiopharmaceutical for the visualization of metastatic prostate cancer. Data presented at the Annual Congress of the European Association of Nuclear Medicine in Vienna demonstrated that Trofex rapidly detected prostate cancer localized in the prostate bed, soft tissues and bone within four hours post injection. In contrast, ProstaScint required five days before imaging and was unable to detect metastatic disease in bone.

Trofex is a radiolabeled, small-molecule that binds prostate specific membrane antigen, a protein highly expressed by prostate cancer cells, with high affinity and specificity. The high degree of uptake and retention of Trofex in prostate cancer cells allows for non-invasive molecular imaging of prostate cancer.

Data from two completed Phase 1 studies and preliminary data from one ongoing Phase 1 study were presented in an abstract titled: Detection of Metastatic Prostate Cancer in Soft Tissue, Bone, and Prostate with 123I-MIP-1072: A Comparison with 111In-Capromab Pendetide. John W. Babich, Ph.D., MIPI Executive Vice President, Chief Scientific Officer and President of Research and Development, senior author of the study, presented the data from these studies.

MIPI, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. MIPI develops its lead radiotherapeutic oncology product candidate, Azedra, which is in pivotal Phase IIb trials for the treatment of pheochromocytoma/paraganglioma in adults and neuroblastoma in children; and MIPI's lead radiotherapeutic product candidate, Onalta, which is in European pivotal Phase III clinical studies for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. MIPI is developing a non-oncology product, Zemiva, a molecular cardiovascular imaging radiopharmaceutical product candidate, which completed the Phase II trials for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart muscle. MIPI sub-licensed Onalta to BioMedica Life Sciences S.A. for development in certain countries in Europe, the Middle East, north Africa, Russia, and Turkey under a strategic collaboration agreement. MIPI was founded in 1997 and is based in Cambridge, Massachusetts.

To learn more about MIPI visit:  http://www.molecularinsight.com

*************************************************************

  Crown Equity Holdings Inc. (OTCPK:CRWE)

On line media is no longer a luxury reserved for the big companies

The executive management team at CRWE has considerable knowledge and experience in the securities industry and is available for consultation.

Forms for additional resources including a comprehensive list of State and Federal business forms are available at the CRWE website.

CRWE has launched its crwenewswire.fr website to provide news in France’s native language and is launching CRWE's Canadian website crwenewswire.ca shortly. CRWE had previously launched its German website:  crwenewswire.de

“The new website is one step in many towards CRWE ’s goal of expanding its footprint internationally,” commented Kenneth Bosket, President and CEO of CRWE “Our goal for 2010 is to have all CRWE’s clients’ press releases, articles and news content published in every major financial country’s native language, as well as within cities of every state of our country,” stated Mr. Bosket.

In other company news, CRWE announces that its sales this year have already surpassed $1,000,000. This compares to $232,510 for the three quarters ending September 30, 2009 and $ 659,907 total sales for the year 2009.

“Based on our sales to date, we had more than 4 times the sales for the same period last year and are 34% ahead of last year’s total sales,” commented Kenneth Bosket, President and CEO of CRWE. “Our growth in sales along with our investments in infrastructure and people give the company a basis for supporting future growth of the magnitude we have seen so far this year,” stated Bosket.

CRWE has expanded internationally through the internet to include the following 19 countries: Argentina, Australia, Brazil, Canada, China, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Korea, Mexico, New Zealand, Singapore, Spain, Taiwan and the UK.

CRWE is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused CRWE’s primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.

To learn more about CRWE visit:  http://www.crownequityholdings.com

___

 

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

http://stock-pr.com/img/stock-pr_buscard.jpg

________________________________________

Be Sure To Visit stock-pr.ning.com

**********************************************************************

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.